Successful Treatment of Refractory IgA‐Mediated Autoimmune Hemolytic Anemia With Bortezomib
eJHaem · 2025-12 · 6 (6)
DOI: 10.1002/jha2.70162 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 25.10.2025. Verfasst von Silvia Neri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sanquin Research and Landsteiner Laboratory of the Academic Medical Center University of Amsterdam Amsterdam the Netherlands. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
IgA‐mediated autoimmune hemolytic anemia (AIHA) is a rare condition associated with severe hemolysis and limited therapeutic response. Bortezomib, a proteasome inhibitor, targets plasma cells responsible for autoantibody production. Here, we describe a case of refractory IgA‐mediated AIHA in a 13‐year‐old boy presenting with severe hemolysis, who was successfully treated with bortezomib.
Methods
Blood samples were collected at different time points throughout the disease course for immunohematology testing.
Results
The patient showed significant hematologic improvement following four doses of Bortezomib with reduction in hemolysis and recovery of hemoglobin levels. Laboratory tests revealed complement‐negative, Coombs‐positive blood tests combined with altered RBC morphology. Phagocytosis of patient's RBC was absent at all timepoints. Notably, despite hematologic improvement, IgA‐positive RBC remained present, accompanied by compensated hemolysis.
Conclusions
The present case demonstrates the potential of bortezomib as a treatment option for refractory AIHA cases, particularly in children. Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission
Autor:innen und Institutionen
- Sanquin Research and Landsteiner Laboratory of the Academic Medical Center University of Amsterdam Amsterdam the Netherlands.
- Department of Pediatric Hematology Location Academic Medical Center (AMC), Emma Children's Hospital, Amsterdam UMC, University of Amsterdam Amsterdam the Netherlands.
- Department of Pediatric Infectious Disease Location Academic Medical Center (AMC), Emma Children's Hospital, Amsterdam UMC, University of Amsterdam Amsterdam the Netherlands.
- Sanquin Diagnostic Services Amsterdam the Netherlands.
- Department of Hematology Amsterdam UMC, University of Amsterdam Amsterdam the Netherlands.
ORCID-Profile: Silvia Neri, Robin van Bruggen
Zitieren
APA
Neri, S., Eckhardt, C. L., Beuger, B. M., Folman, F., Rettenbacher, E., Matlung, H. L., Kuijpers, T. W., Vos, J. M. I., & van Bruggen, R. (2025). Successful Treatment of Refractory IgA‐Mediated Autoimmune Hemolytic Anemia With Bortezomib. eJHaem, 6(6). https://doi.org/10.1002/jha2.70162
Vancouver
Neri S, Eckhardt CL, Beuger BM, Folman F, Rettenbacher E, Matlung HL, et al. Successful Treatment of Refractory IgA‐Mediated Autoimmune Hemolytic Anemia With Bortezomib. eJHaem. 2025;6(6). doi:10.1002/jha2.70162
BibTeX
@article{Neri2025,
author = {Neri, Silvia and Eckhardt, Corien L and Beuger, Boukje M and Folman, Folman and Rettenbacher, Eva and Matlung, Hanke L and Kuijpers, Taco W and Vos, Josephine M I and van Bruggen, Robin},
title = {Successful Treatment of Refractory IgA‐Mediated Autoimmune Hemolytic Anemia With Bortezomib},
journal = {eJHaem},
year = {2025},
volume = {6},
number = {6},
doi = {10.1002/jha2.70162}
}
EUVIMED